% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Santacroce:306670,
      author       = {A. Santacroce and A. Muacevic and N. Kohlhase and D.
                      Eftimova and T. Hofmann and M. Sammer and A. Graser and M.
                      Kufeld and C. Fürweger and F. Ehret$^*$},
      title        = {{G}yroscopic {R}adiosurgery - {C}linical {E}xperience and
                      {P}rospective {A}nalysis of over 500 {T}reated {T}umors.},
      journal      = {World neurosurgery},
      volume       = {nn},
      issn         = {1878-8750},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-02663},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Stereotactic radiosurgery (SRS) plays a significant role in
                      the treatment of various benign and malignant tumors of the
                      central nervous system. Recently, the first self-shielding
                      treatment platform for gyroscopic radiosurgery (GRS) was
                      introduced. Herein, we report our experience with GRS
                      treatment of the first 541 tumors in a prospective
                      setting.This study enrolled patients who underwent GRS for
                      intracranial tumors. Patient, treatment, and outcome data
                      were prospectively collected and analyzed. Only patients
                      with at least one imaging and clinical follow-up were
                      included in this analysis. Volumetric assessments and major
                      toxicity are presented.A total of 491 patients were treated
                      between 2021 and 2024. Of those, 382 patients harboring 541
                      tumors underwent at least one imaging and clinical
                      follow-up. The majority of tumor entities treated were
                      vestibular schwannomas (196), brain metastases (188), and
                      meningiomas (113). The median prescription dose for brain
                      metastases was 20 Gy. For meningiomas and vestibular
                      schwannomas, the median prescription doses were 15 and 13
                      Gy, respectively. Analysis of dosimetric performance showed
                      that GRS treatments are highly conformal, achieving steep
                      dose gradients. The median imaging follow-up was 10.6
                      months. Volumetry of the treated targets demonstrated an
                      early treatment effect, with either tumor volume reduction
                      or stability for most tumors.The early results of this
                      prospective study, which enrolls patients undergoing GRS,
                      show the efficacy and safety of the new self-shielding
                      treatment platform. Due to the limited follow-up of this
                      analysis, future studies including long-term outcome data
                      are needed.},
      keywords     = {ZAP-X (Other) / brain metastasis (Other) / gyroscopic
                      radiosurgery (Other) / meningioma (Other) / radiosurgery
                      (Other) / stereotactic radiosurgery (Other) / vestibular
                      schwannoma (Other)},
      cin          = {BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41318094},
      doi          = {10.1016/j.wneu.2025.124684},
      url          = {https://inrepo02.dkfz.de/record/306670},
}